Stockbabie NewsFatherMarketNewsMarket Intelligence
Subscribe
MARKETS
Wire · Markets
Markets

Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clinical Study Of EB103 In Participants With Relapsed Or Refractory B-Cell Non-Hodgkin’s Lymphoma

Jul 29, 2026 · 08:05 AM ET· updated 3h ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and

Share
Why It Matters

Estrella is opening a second place to test a new cancer medicine on more patients. This shows the company believes in its treatment and is moving forward with its plan.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
ESLA0.75
+0.00 (+0.60%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.